Navigation Links
American Oriental Bioengineering Announces Participation in September Investor Conferences
Date:9/4/2007

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced that the Company will attend the Credit Suisse Asian Technology Conference -- China Day on September 10, 2007 in Shenzhen, China as well as the 3rd Semi-Annual Investor Tour of Mainland China hosted by Brean Murray Carret & Co. on September 11, 2007 in Beijing, China.

AOBO management will meet individually with institutional investors attending the Credit Suisse Asian Technology Conference at the Crowne Plaza Hotel in Shenzhen, China on September 10, 2007. In addition, Tony Liu, CEO of AOBO will join a lunch panel discussion at 1:00 pm Beijing Standard Time along with presenters from other Chinese healthcare companies to discuss the recent developments in the China's healthcare industry. Investors interested in attending this event should contact their Credit Suisse institutional sales representative.

AOBO management is scheduled to present at the Brean Murray China Tour on September 11, 2007 at 12:00 pm Beijing Standard Time at the Grand Hyatt Hotel in Beijing. Attendees are also invited to tour the Company's pharmaceutical manufacturing facility and nutraceutical manufacturing facility in Harbin, China on Saturday, September 8, 2007. Investors interested in attending this event should contact their Brean Murray institutional sales representative.

ABOUT AMERICAN ORIENTAL BIOENGINEERING INC:

American Oriental Bioengineering Inc. (AOBO) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throug
'/>"/>

SOURCE American Oriental Bioengineering, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. A disgusting video: U.S. companies sell out Americans
2. Northwestern Mutual, American Family make Computerworlds best IT workplaces
3. Brazilian bio-industry should impress American investors
4. CIO Leadership Series: Byrne Chapman, American Family Insurance
5. Metavante fires 180 North American workers
6. 300 millionth American no cause for eco-alarm
7. American Idol spurs music software
8. Healthcare software addresses "90 million" misclassified Americans
9. Technology and the "American" dream
10. Peters: Innovation the only edge that remains for American business
11. We are American No sex, please
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... CORALVILLE, Iowa, Dec. 4 Vivakor, Inc. (OTC Bulletin ... on December 1, 2009 will receive the dividend of ... previously approved by Vivakor,s Board of Directors. HealthAmerica ... approximately 84% of the outstanding common shares on the ...
(Date:12/4/2009)... Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin ... fuel paradigm through the production of ethanol from non-food cellulosic ... Digest list of the "50 Hottest Companies in Bioenergy;" ... ,, "Having voters rank BlueFire Ethanol among the top 20 ...
(Date:12/3/2009)... ACCESS PHARMACEUTICALS, INC. ... on its European commercial launch of MuGard, an FDA ... of radiation treatment and chemotherapy. MuGard is commercially launched ... the UK, Germany, Italy, Norway, Greece and Sweden. Access ...
(Date:12/3/2009)... Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ... the second quarter of fiscal year 2010 on December 10, ... call and webcast to discuss the results at 11:30 a.m. ... discuss financial results for the second quarter ended October 31, ...
Breaking Biology Technology:Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
... SAN DIEGO, June 18 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced that it ... to be held in New York on June ... and Chief Executive Officer,will present on Wednesday, June ...
... June 18 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX:,MS), a ... today,announced that Mr. Kevin Giese, President and CEO, will ... York., WHEN: Wednesday June 25th ... New York, About the Jefferies 2nd Annual Healthcare ...
... BCRX ) today announced that William P. ... of BioCryst, effective July 1,2008. Dr. Sheridan is ... President of North American Medical Affairs at Amgen, ... Simon, who has been with,the Company since January ...
Other Biology Technology:Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference 2BioMS Medical to present at Jefferies Healthcare Conference 2William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 2William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 3William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 4
(Date:12/3/2009)... of scientists from the U.S. Department of Energy,s (DOE) ... of Science has made a major step in understanding ... is necessary to carry out important biological processes. The ... Nature Structural & Molecular Biology , confirms that ...
(Date:12/2/2009)... PHILADELPHIA Less acculturated Latino men have a more ... acculturated to U.S. culture, but acculturation has no affect ... findings are published in Cancer Epidemiology, Biomarkers & ... Cancer Research. The December issue has a special focus ...
(Date:12/2/2009)... within minutes after waking up have much higher levels of ... than those who wait to smoke, regardless of the number ... appear to reflect the risk of lung cancer, our results ... especially at risk for lung cancer," said researcher Joshua E. ...
Breaking Biology News(10 mins):Grooving down the helix 2Grooving down the helix 3Acculturation affects smoking cessation success among Latinos 2Increased nicotine levels detected in those who light-up earlier 2Selexis and Neogenix Oncology Announce Agreement on Antibody Project 57950 1Selexis and Neogenix Oncology Announce Agreement on Antibody Project 57950 2TrinityCare Senior Living Announces Expansion into Louisiana 57948 1TrinityCare Senior Living Announces Expansion into Louisiana 57948 2TrinityCare Senior Living Announces Expansion into Louisiana 57948 3Moroney 26 Gill Inc Launches New Website 57946 1
... A. Rosenberg, M.D., at the National Cancer Institute, part ... patients with advanced melanoma who had not responded to ... of their cancers as a result of receiving a ... chemotherapy and reintroduction of their own (autologous) activated lymphocytes. ...
... have found that the cause of chronic sinus infections lies ... the nasal and sinus tissue targeted by standard treatment. The ... of Allergy and Clinical Immunology and are available online ... worldwide about the origin of chronic sinus infection: that inflammatory ...
... A new method for manipulating macromolecules has been developed ... The technique uses double-stranded DNA to direct the behavior ... duplex DNA has been used as a static lattice ... manipulating DNA alone into such shapes, the researchers are ...
Other Biology News:NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma 2Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show It's Snot 2UN successfully tests 'green' pesticide against locusts 2
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
GBL Antibody...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: